Compare ASE Technology Holding Co Ltd (ASX) vs Pfizer Inc (PFE) Price & Performance

ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.

Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.

Pfizer (PFE) trades at $24.17, down 0.33% over the past day, with a bearish technical signal from moving averages. The company maintains solid profitability with a net income margin of 11.83% and has beaten EPS estimates in three consecutive quarters. Recent news highlights pipeline advancements in obesity and oncology, with a dividend yield supported by consistent payouts.

Outlook remains mixed; analyst consensus suggests 15% upside to the $27.71 price target, but patent cliffs and revenue normalization post-COVID pose risks. The stock presents value at a P/E of 18.45, though investor sentiment is cautious amid competitive pressures and debt levels near 30% of assets.